María Florencia Ladetto

Ms. María Florencia Ladetto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
MLMaría Florencia Ladetto
María Florencia Ladetto
Juan Manuel Lázaro-MartínezJuan Manuel Lázaro-Martínez
Juan Manuel Lázaro-Martínez
TDTomás Brito Devoto
Tomás Brito Devoto
VBVíctor J. Briceño
Víctor J. Briceño
Guillermo Raul CastroGuillermo Raul Castro
Guillermo Raul Castro
MCMaria Cuestas
Maria Cuestas
Voriconazole (VCZ) is a triazolic drug used to treat serious fungal infections and invasive mycosis and has also been more recently used as a generic antifungal treatment. However, VCZ therapies can cause undesirable side effects and doses must be carefully monitored before administration to avoid or reduce severe toxic effects. Analytical techniques used to quantify VCZ are mostly based on HPLC/UV and often associated with multiple technical steps as well as expensive equipment. The present work aimed to develop an accessible and affordable spectrophotometric technique in the visible range (λ = 514 nm) for the simple quantification of VCZ. The technique was based on VCZ-induced reduction of thionine (TH, red) to leucothionine (LTH, colorless) under alkaline conditions. The reaction showed a linear correlation over the range of 1.00 μg mL−1 to 60.00 μg mL−1 at room temperature, the limits of detection and quantification being 1.93 μg mL−1 and 6.45 μg mL−1, respectively. VCZ degradation products (DPs) according to 1H and 13C-NMR spectrometric determinations not only showed good agreement with the ones previously reported (DP1 and DP2 – T. M. Barbosa, G. A. Morris, M. Nilsson, R. Rittner and C. F. Tormena, RSC Adv., 2017, DOI: 10.1039/c7ra03822d), but also revealed a new degradation product (DP3). Mass spectrometry not only confirmed the presence of LTH as a result of the VCZ DP-induced TH reduction, but also revealed the formation of a novel and stable Schiff base as a reaction product between DP1 and LTH. The latter finding became significant as it stabilizes the reaction for quantification purposes, by hindering LTH ↔TH redox reversibility. This analytical method was then validated according to the ICH Q2 (R1) guidelines, and additionally, it could be demonstrated as applicable for the reliable VCZ quantification in commercially available tablets. Importantly, it also represents a useful tool for detecting toxic threshold concentrations in human plasma from VCZ-treated patients, alerting when these risky limits are exceeded. In this way, this technique independent from sophisticated equipment, highly qualifies as a low-cost, reproducible, trustable, and non-laborious alternative method for VCZ measurements from different matrices.

12 August 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MLMaría Florencia Ladetto
María Florencia Ladetto
MAMaría Eugenia Ancarola
María Eugenia Ancarola
DLDiego German Lamas
Diego German Lamas
BKBianca A. Kollrich
Bianca A. Kollrich
MCMarcela A. Cucher
Marcela A. Cucher
MCMaria Cuestas
Maria Cuestas

30 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SCShaul Cemal
Shaul Cemal
MLMaría Florencia Ladetto
María Florencia Ladetto
KAKatherine Hermida Alava
Katherine Hermida Alava
GKGila Kazimirsky
Gila Kazimirsky
MCMarcela Cucher
Marcela Cucher
Gerardo BykGerardo Byk
Gerardo Byk
Background/Objectives: Filamentous fungi, in particular the species Aspergillus, Scedosporium, and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, particularly in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Methods: Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated via dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids, indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for the release of VRC under two different sink conditions. Results: Notably, the antifungal activity of VRC-loaded nanohydrogels was up to eight-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. Conclusions: These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.

24 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShaul Cemal
Shaul Cemal
MLMaría Florencia Ladetto
María Florencia Ladetto
KAKatherine Hermida Alava
Katherine Hermida Alava
GKGila Kazimirsky
Gila Kazimirsky
MCMarcela Cucher
Marcela Cucher
Gerardo BykGerardo Byk
Gerardo Byk
Filamentous fungi, in particular the species Aspergillus, Scedosporium and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, in particular in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers, were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated by dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for release of VRC under two different sink conditions. Notably, the antifungal activity of VRC-loaded nanohydrogels was at least two-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.